Glaxo to double R&D staff in China

GlaxoSmithKline is making ambitious plans to expand its R&D operations in China. According to Glaxo's Carol Zhu, who runs the operation, the company will more than double the number of researchers it has on staff in China. The R&D arm will grow from a staff of 170 today to 200 by year's end and plans to reach 350 next year. The pharma giant then plans to hold staffing at that level for several years before adding new researchers.

- read the report from Healthcare Digital

Suggested Articles

UPMC researchers are planning clinical trials of a COVID-19 vaccine that uses pieces of the virus' spike protein to create immunity.

Treating mice with niacin increased the number of immune cells in glioblastomas, reducing tumor size and extending survival.

Efforts to pivot existing discoveries into COVID-19 cures may not bear fruit until the pandemic has ended but could help fend off future outbreaks.